ERBB2 and inflammatory breast carcinoma: BEVERLY-1 trial (NCT00820547)[3] is a phase 2 study designed to determine the efficacy and safety of the combination of bevacizumab with neoadjuvant and adjuvant chemotherapy in patients with non-metastatic inflammatory breast cancer without HER2 overexpression